Nexalin Technology Awarded Patent Bt USPTO Related To Its Deep Intracranial Frequency Stimulation Device For Treatment Of Alzheimer's And Dementia
Portfolio Pulse from Benzinga Newsdesk
Nexalin Technology has been awarded a patent by the USPTO for its Deep Intracranial Frequency Stimulation device, which is used for the treatment of Alzheimer's and dementia.
June 20, 2024 | 12:36 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Nexalin Technology has received a patent for its Deep Intracranial Frequency Stimulation device, which is designed to treat Alzheimer's and dementia. This patent could enhance the company's market position and drive future revenue growth.
The patent approval is a significant milestone for Nexalin Technology as it validates their technology and could lead to increased adoption and sales. This development is likely to positively impact the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100